Composition : Toposar : Each 5 ml lnjectable solution contains Etoposide USP 100mg.
Indication : Etoposide is indicated in the management of the following neoplasms: Small Cell Lung Cancer: Etoposide is indicated in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Refractory Testicular Tumors: Etoposide is also indicated in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic, and radio therapeutic therapy
Dosage and administration : Small cell lung cancer: The dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Refractory Testicular Tumors: The usual dose of Etoposide in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5. For recommended dosing adjustments in patients with renal impairment chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.Or, as directed by the registered physicians
Use in pregnancy and lactation : Pregnancy category D.There are no adequate and well controlled studies in pregnant woman Etoposide has been reported to be found in human milk. Patient recieves Etoposide should not be breast feed.
Packing : Toposar: Each box contains one vial of 5ml solution